Bhm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Hauske SJ, Schueler E, Wanner C, Verma S, Zannad F, Packer M, Anker SD
The mice were pretreated with dopamine antagonist haloperidol (5.0 mg/kg i.p.) and subsequently treated with amphetamine (20 mg/kg i.p.1, 2, 4 and 10 days after haloperidol pre-treatment), which is usually used for the study of behavioral supersensitivity to an amphetamine stimulating effect
Patients and healthcare professionals are encouraged to report any suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app
The initial model was rigid-body fitted into the consensus EM density map via UCSF Chimera 1.14 32 , followed by manual adjustment using ISOLDE 33 embedded in UCSF ChimeraX 1.6 34